利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.02 秒)

    METHOD FOR PRODUCING TWO-DIMENSIONALLY PATTERNED CARBON NANOTUBE AND TWO-DIMENSIONALLY PATTERNED CARBON NANOTUBE
    1.
    发明申请
    METHOD FOR PRODUCING TWO-DIMENSIONALLY PATTERNED CARBON NANOTUBE AND TWO-DIMENSIONALLY PATTERNED CARBON NANOTUBE 审中-公开
    用于生产二维图形碳纳米管和二维图案碳纳米管的方法

    公开(公告)号：US20110311763A1

    公开(公告)日：2011-12-22

    申请号：US13203705

    申请日：2010-02-26

    申请人： Shigeo Maruyama ,  Rong Xiang

    发明人： Shigeo Maruyama ,  Rong Xiang

    IPC分类号： B32B3/10 ,  B32B7/00 ,  G03F7/20 ,  B32B5/16 ,  B82Y30/00 ,  B82Y40/00

    CPC分类号： C01B32/162 ,  B01J23/28 ,  B01J23/745 ,  B01J23/75 ,  B01J23/755 ,  B01J23/882 ,  B01J37/0217 ,  B01J37/0228 ,  B82Y30/00 ,  B82Y40/00 ,  C01B32/15 ,  C01B2202/02 ,  C01B2202/04 ,  C01B2202/08 ,  G03F7/20 ,  G03F7/2059 ,  G03F7/40 ,  Y10T428/24174 ,  Y10T428/24893

    摘要： Disclosed are a method for producing a carbon nanotube (CNT) whereby, in the local synthesis of CNTs, a high resolution, a low cost, easiness in production and mass production capability can be established at the same time; and a two-dimensionally patterned CNT obtained thereby. Specifically disclosed are a method for producing a two-dimensionally patterned CNT which comprises: A) a step for preparing a substrate; B) a step for forming a first two-dimensional pattern, which consists of hydrophobic surface and hydrophilic surface, on the substrate by means of 1) masking and electromagnetic wave irradiation, or 2) electron beam irradiation; C) a step for applying a catalyst-containing solution to the substrate having the first two-dimensional pattern and forming a second two-dimensional pattern depending on the presence or absence of the catalyst; and D) a step for forming by ACCVD a two-dimensional pattern of the CNT on the thus obtained substrate; a substrate; and a structure comprising a two-dimensionally patterned CNT on the aforesaid substrate.

    摘要翻译： 公开了一种碳纳米管（CNT）的制造方法，其中，在CNT的局部合成中，可以同时建立高分辨率，低成本，易于生产和批量生产的能力; 和由此获得的二维图案化的CNT。 具体公开了二维图案化CNT的制造方法，其特征在于，包括：A）准备基板的工序; B）通过1）掩蔽和电磁波照射，或2）电子束照射，在衬底上形成由疏水表面和亲水表面组成的第一二维图案的步骤; C）将具有催化剂的溶液施加到具有第一二维图案的基板并根据催化剂的存在或不存在而形成第二二维图案的步骤; 以及D）通过ACCVD在由此获得的衬底上形成CNT的二维图案的步骤; 底物; 以及包括在上述基板上的二维图案化CNT的结构。

    DNA vaccines against tumor growth and methods of use thereof
    4.
    发明授权
    DNA vaccines against tumor growth and methods of use thereof 有权
    针对肿瘤生长的DNA疫苗及其使用方法

    公开(公告)号：US08716254B2

    公开(公告)日：2014-05-06

    申请号：US10807897

    申请日：2004-03-24

    申请人： Rong Xiang ,  He Zhou ,  Ralph A. Reisfeld

    发明人： Rong Xiang ,  He Zhou ,  Ralph A. Reisfeld

    IPC分类号： A61K39/00 ,  A61K6/00

    CPC分类号： A61J1/05 ,  A61K6/00 ,  A61K39/0011 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  Y02A50/484

    摘要： A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA, human MICB, human ULBP1, human ULBP2, and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the invention to a mammal is also described.

    摘要翻译： 适用于引发针对癌细胞的免疫应答的DNA疫苗包括可操作地编码癌相关的凋亡家族蛋白抑制剂的DNA构建体和免疫活性基因产物，例如细胞因子或天然杀伤细胞表面受体的配体， 药学上可接受的载体。 优选的细胞因子是CCL21。 用于天然杀伤细胞表面受体的优选配体包括人MICA，人MICB，人ULBP1，人ULBP2和人ULBP3。 癌症相关的凋亡抑制剂（IAP）家族蛋白质优选是存活蛋白质蛋白质或livin蛋白质。 还描述了通过将哺乳动物施用本发明的疫苗来抑制肿瘤生长的方法。

    DNA vaccines against tumor growth and methods of use thereof
    5.
    发明申请
    DNA vaccines against tumor growth and methods of use thereof 失效
    针对肿瘤生长的DNA疫苗及其使用方法

    公开(公告)号：US20100136058A1

    公开(公告)日：2010-06-03

    申请号：US12462496

    申请日：2009-08-04

    申请人： Yunping Luo ,  Rong Xiang ,  Ralph A. Reisfeld

    发明人： Yunping Luo ,  Rong Xiang ,  Ralph A. Reisfeld

    IPC分类号： A61K39/02 ,  A61K39/00 ,  C12N1/21

    CPC分类号： A61K48/0008 ,  A61K39/0011 ,  A61K48/005 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/6031 ,  C12N2510/02 ,  Y02A50/484

    摘要： A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium, particularly a doubly attenuated aroA- dam- S. typhimurium. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.

    摘要翻译： 适用于引发针对癌细胞的免疫应答的DNA疫苗包括在药学上可操作地编码Fra-1蛋白（例如多聚遍在蛋白化的人Fra-1蛋白）和IL-18（例如人IL-18）的多核苷酸构建体 可接受的载体 在优选的实施方案中，多核苷酸构建体可操作地掺入减毒的细菌载体中，例如减毒的鼠伤寒沙门氏菌，特别是双重减毒的aroA-鼠伤寒沙门氏菌。 还描述了转化的宿主细胞，抑制肿瘤生长的方法，使患者接种癌症的疫苗，以及将体内遗传物质递送至哺乳动物细胞。

    DNA vaccines against tumor growth and methods of use therof
    6.
    发明授权
    DNA vaccines against tumor growth and methods of use therof 失效
    针对肿瘤生长的DNA疫苗及其使用方法

    公开(公告)号：US07569552B2

    公开(公告)日：2009-08-04

    申请号：US10574752

    申请日：2004-10-07

    申请人： Yunping Luo ,  Rong Xiang ,  Ralph A. Reisfeld

    发明人： Yunping Luo ,  Rong Xiang ,  Ralph A. Reisfeld

    IPC分类号： A01N43/04 ,  A61K48/00

    CPC分类号： A61K48/0008 ,  A61K39/0011 ,  A61K48/005 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55527 ,  A61K2039/6031 ,  C12N2510/02 ,  Y02A50/484

    摘要： A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium, particularly a doubly attenuated aroA− dam− S. typhimurium. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.

    摘要翻译： 适用于引发针对癌细胞的免疫应答的DNA疫苗包括在药学上可操作地编码Fra-1蛋白（例如多聚泛素化的人Fra-1蛋白）和IL-18（例如人IL-18）的多核苷酸构建体 可接受的载体 在优选的实施方案中，多核苷酸构建体可操作地掺入减毒的细菌载体中，例如减毒的鼠伤寒沙门氏菌，特别是双重减毒的aroA-鼠伤寒沙门氏菌。 还描述了转化的宿主细胞，抑制肿瘤生长的方法，使患者接种癌症的疫苗，以及将体内遗传物质递送至哺乳动物细胞。

    DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof
    7.
    发明申请
    DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof 有权
    编码免疫原性VEGF受体肽的DNA组合物及其使用方法

    公开(公告)号：US20070059323A1

    公开(公告)日：2007-03-15

    申请号：US11507298

    申请日：2006-08-21

    申请人： Ralph Reisfeld ,  Andreas Niethammer ,  Rong Xiang

    发明人： Ralph Reisfeld ,  Andreas Niethammer ,  Rong Xiang

    IPC分类号： A61K48/00 ,  A61K39/02

    CPC分类号： A61K39/0005 ,  A61K39/0011 ,  A61K2039/522 ,  A61K2039/53 ,  A61K2039/542 ,  Y02A50/484

    摘要： A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

    摘要翻译： 有效抑制内皮细胞增殖的DNA组合包括可操作地编码血管内皮生长因子（VEGF）受体多肽的DNA构建体，其可以是全长VEGF受体蛋白质或其免疫原性片段。 本发明提供编码VEGF受体-2（KDR），VEGF受体-1（Flt-1）或Flk-1（KDR的鼠同源物）的DNA组合物，以及使用这种DNA组合物抑制血管的方法 内皮细胞增殖在肿瘤微环境中。 实现血管发生抑制和随后肿瘤生长和传播的减少。

    DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
    9.
    发明申请
    DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof 失效
    编码CEA和CD40配体的DNA疫苗及其使用方法

    公开(公告)号：US20050287123A1

    公开(公告)日：2005-12-29

    申请号：US11195506

    申请日：2005-08-02

    申请人： Rong Xiang ,  Ralph Reisfeld

    发明人： Rong Xiang ,  Ralph Reisfeld

    IPC分类号： C12N15/09 ,  A61J1/14 ,  A61K35/74 ,  A61K35/76 ,  A61K38/00 ,  A61K39/00 ,  A61K39/39 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C12N15/12 ,  C12N15/19 ,  C12N15/63 ,  C07H21/04

    CPC分类号： A61K39/0011 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55533 ,  C07K14/70503 ,  C07K14/70575

    摘要： A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.

    摘要翻译： 有效地引发针对呈现癌胚抗原（CEA）的细胞的免疫应答的DNA疫苗分别包含可操作地编码CEA的DNA和可操作地编码CD40配体SEQ ID NO：1和SEQ ID NO：2的DNA，或 其同源三聚体，CD40LT。 DNA疫苗可以并入递送载体如减毒活细菌或病毒或脂质体载体中。 在方法实施方案中，将DNA疫苗口服给予哺乳动物（例如人）以引发针对CEA呈递细胞例如结肠癌细胞的免疫应答。 优选的方法实施方案包括用重组抗体融合蛋白huKS1 / 4-IL2处理哺乳动物以增强疫苗的免疫应答有效性的附加步骤。